Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat.

R A Ahokas1, W C Mabie, B M Sibai

  • 1Department of Obstetrics and Gynecology, University of Tennessee, Memphis 38163.

American Journal of Obstetrics and Gynecology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relationship between delivery and the PaO<sub>2</sub> /FiO<sub>2</sub> ratio in COVID-19: a cohort study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

An aspirin a day in pregnancy keeps childhood hypertension away?

BJOG : an international journal of obstetrics and gynaecology·2019
Same author

Uterine balloon tamponade for the management of postpartum haemorrhage: a challenge and an opportunity for better evidence.

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

The benefits/risks of treatment of non-severe hypertension in pregnancy and choice of drug remain unanswered.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP.

Pregnancy hypertension·2015
Same author

OS003. The influence of gestational weight gain on the development ofgestational hypertension in obese women.

Pregnancy hypertension·2015
Same journal

Trends in Infertility Treatments by Race, Ethnicity, Socioeconomic Status, and Region in U.S. Birth Certificates from Live Births: 2011-2022.

American journal of obstetrics and gynecology·2026
Same journal

Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

American journal of obstetrics and gynecology·2026
Same journal

Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

American journal of obstetrics and gynecology·2026
Same journal

Early life adversity and polycystic ovary syndrome among North American pregnancy planners.

American journal of obstetrics and gynecology·2026
See all related articles

Labetalol hydrochloride effectively lowered blood pressure in hypertensive pregnant rats by reducing cardiac output, primarily through beta-adrenergic blockade. This hypertension drug did not significantly alter placental perfusion, suggesting its potential use in pregnancy.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology
  • Reproductive Medicine

Background:

  • Hypertension in pregnancy poses risks to both mother and fetus.
  • Labetalol, a combined alpha- and beta-blocker, is used to manage hypertensive emergencies.
  • Its specific effects on maternal hemodynamics and organ perfusion during pregnancy require further elucidation.

Purpose of the Study:

  • To investigate the acute effects of labetalol hydrochloride on maternal hemodynamics and organ perfusion in hypertensive, pregnant rats.
  • To determine the primary mechanism of blood pressure reduction by labetalol in this model.
  • To assess the impact of labetalol on placental perfusion.

Main Methods:

  • Utilized the radioactive-labeled microsphere technique in 10 hypertensive, term-pregnant rats.

Related Experiment Videos

  • Litter size was reduced to prevent the normal fall in blood pressure during pregnancy.
  • Administered labetalol hydrochloride at doses of 1 to 6 mg/kg.

    • Main Results:

    • Labetalol significantly lowered mean arterial pressure by 22% and decreased cardiac output by 16%.
    • Total peripheral resistance was not significantly affected, indicating the blood pressure reduction was mainly due to beta-adrenergic blockade.
    • Regional flows to the carcass and splanchnic circulation decreased, while uterine and ovarian perfusion were reduced; however, placental perfusion remained unaltered.

    Conclusions:

    • Labetalol effectively reduces blood pressure in hypertensive pregnant rats primarily via its beta-adrenergic blocking action.
    • Despite reductions in some regional flows, placental perfusion was not compromised.
    • Labetalol may serve as a viable alternative to hydralazine for treating hypertensive emergencies in pregnancy due to its favorable effect on placental blood flow.